Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

The findings come after reports of nasty side effects - including eye problems, infections and gastrointestinal disorders - ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

President Trump's new Executive Order aims to lower prescription drug prices by tying U.S. costs to global rates. Read more ...

In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk's own treatment, Eli Lilly said of the results presented at the European Congress ...

The first head-to-head trial of two blockbuster weight-loss drugs has shown Mounjaro is more effective than rival Wegovy.

The first head-to-head trial of obesity drugs reveals a clear winner for effective weight loss. But how does it work, and what are the long-term effects? Anna Magee reports ...

Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.